JP7852904B2 - 免疫調節抗体およびその使用方法 - Google Patents

免疫調節抗体およびその使用方法

Info

Publication number
JP7852904B2
JP7852904B2 JP2021578268A JP2021578268A JP7852904B2 JP 7852904 B2 JP7852904 B2 JP 7852904B2 JP 2021578268 A JP2021578268 A JP 2021578268A JP 2021578268 A JP2021578268 A JP 2021578268A JP 7852904 B2 JP7852904 B2 JP 7852904B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
antibody
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021578268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540806A5 (cg-RX-API-DMAC7.html
JP2022540806A (ja
Inventor
ディー. プリ,カマル
チャンドラセカラン,シッダース
エル. コネリー,メリッサ
エム. シモンズ,ランディ
ティー. スミス,タイレル
イー. ブラナム,マーク
プロブスト,ピーター
Original Assignee
オンコレスポンス,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコレスポンス,インク. filed Critical オンコレスポンス,インク.
Publication of JP2022540806A publication Critical patent/JP2022540806A/ja
Publication of JP2022540806A5 publication Critical patent/JP2022540806A5/ja
Priority to JP2025181128A priority Critical patent/JP2026026087A/ja
Application granted granted Critical
Publication of JP7852904B2 publication Critical patent/JP7852904B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021578268A 2019-07-19 2020-07-17 免疫調節抗体およびその使用方法 Active JP7852904B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025181128A JP2026026087A (ja) 2019-07-19 2025-10-27 免疫調節抗体およびその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962876579P 2019-07-19 2019-07-19
US201962876580P 2019-07-19 2019-07-19
US62/876,579 2019-07-19
US62/876,580 2019-07-19
US201962878265P 2019-07-24 2019-07-24
US62/878,265 2019-07-24
PCT/US2020/042668 WO2021016128A1 (en) 2019-07-19 2020-07-17 Immunomodulatory antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025181128A Division JP2026026087A (ja) 2019-07-19 2025-10-27 免疫調節抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022540806A JP2022540806A (ja) 2022-09-20
JP2022540806A5 JP2022540806A5 (cg-RX-API-DMAC7.html) 2023-07-26
JP7852904B2 true JP7852904B2 (ja) 2026-04-28

Family

ID=74193810

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021578268A Active JP7852904B2 (ja) 2019-07-19 2020-07-17 免疫調節抗体およびその使用方法
JP2025181128A Pending JP2026026087A (ja) 2019-07-19 2025-10-27 免疫調節抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025181128A Pending JP2026026087A (ja) 2019-07-19 2025-10-27 免疫調節抗体およびその使用方法

Country Status (14)

Country Link
US (6) US11634501B2 (cg-RX-API-DMAC7.html)
EP (1) EP4004051A4 (cg-RX-API-DMAC7.html)
JP (2) JP7852904B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220035452A (cg-RX-API-DMAC7.html)
CN (1) CN114423787B (cg-RX-API-DMAC7.html)
AU (1) AU2020315878A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000876A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147103A1 (cg-RX-API-DMAC7.html)
IL (1) IL289829A (cg-RX-API-DMAC7.html)
MX (1) MX2022000726A (cg-RX-API-DMAC7.html)
PH (1) PH12022550141A1 (cg-RX-API-DMAC7.html)
TW (1) TW202116809A (cg-RX-API-DMAC7.html)
UY (1) UY38797A (cg-RX-API-DMAC7.html)
WO (1) WO2021016128A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11634501B2 (en) 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
US20240084029A1 (en) * 2021-01-20 2024-03-14 Oncoresponse, Inc. Use of immunomodulatory antibodies to treat fibrotic diseases
MX2023008485A (es) * 2021-01-20 2023-07-28 Oncoresponse Inc Anticuerpos inmunomoduladores y usos de estos.
US11845791B2 (en) * 2021-03-08 2023-12-19 Medimmune, Llc Antibodies directed against GDF-15
WO2023034762A2 (en) * 2021-08-30 2023-03-09 Obi Pharma, Inc. Bispecific dendritic cell engager and uses thereof
WO2023034963A2 (en) * 2021-09-03 2023-03-09 Oncoresponse, Inc. Combinations of immunotherapies and uses thereof
AU2022426854A1 (en) * 2021-12-31 2024-06-13 The Trustees Of Columbia University In The City Of New York Bispecific molecules to target the first cell
EP4615480A1 (en) * 2022-11-07 2025-09-17 Alector LLC Uses of siglec-9 ecd fusion molecules in cancer treatment
JP2026519901A (ja) * 2023-01-27 2026-06-19 ヴィーアイビー ヴィーゼットヴィー Cd163結合複合体
AU2024391672A1 (en) 2023-11-30 2026-05-21 Oncospear Aps Anti-cd163 antibodies with improved adcc capabilities

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100419A1 (en) 2002-05-27 2003-12-04 Bioceros B.V. Methods for using the cd163 pathway for modulating an immune response
WO2018019990A1 (en) 2016-07-28 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatement of cancer disease by targetting tumor associated macrophage
JP2019509017A (ja) 2015-12-30 2019-04-04 メディシナル バイオコンバージェンス リサーチ センター 組換えpicpタンパク質及びこれに特異的に結合する抗体の製造方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE60140069D1 (de) 2000-10-16 2009-11-12 Cytoguide Aps Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür
EP1367393A1 (en) * 2002-05-27 2003-12-03 MacroZyme B.V. Methods for using the CD 163 pathway for modulating an immune response
AU2004204462B2 (en) 2003-01-09 2012-03-08 Macrogenics, Inc. Dual expression vector system for antibody expression in bacterial and mammalian cells
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8053569B2 (en) 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
EP2632955A1 (en) * 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
KR102119840B1 (ko) 2011-07-11 2020-06-09 아이크노스 사이언스 에스. 아. Ox40에 결합하는 항체 및 이들의 용도
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
AU2014213009B2 (en) 2013-02-01 2019-01-03 Kira Biotech Pty Limited Anti-CD83 antibodies and use thereof
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗angptl8抗體及其用途
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
WO2018090144A1 (en) 2016-11-17 2018-05-24 Innovative Targeting Solutions Inc. Chimeric receptors, biosensor host cells and methods/uses thereof
CN110036029A (zh) 2016-11-17 2019-07-19 瑞泽恩制药公司 用抗angptl8抗体处理肥胖的方法
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
CN118271444A (zh) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
CN112424358B (zh) 2018-06-26 2025-07-01 协和麒麟株式会社 与细胞粘附分子3结合的抗体
WO2020018434A1 (en) 2018-07-17 2020-01-23 Scripps Health Compositions and methods for disrupting a macrophage network
WO2020058372A1 (en) 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
US11634501B2 (en) 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
WO2023034963A2 (en) 2021-09-03 2023-03-09 Oncoresponse, Inc. Combinations of immunotherapies and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100419A1 (en) 2002-05-27 2003-12-04 Bioceros B.V. Methods for using the cd163 pathway for modulating an immune response
JP2019509017A (ja) 2015-12-30 2019-04-04 メディシナル バイオコンバージェンス リサーチ センター 組換えpicpタンパク質及びこれに特異的に結合する抗体の製造方法
WO2018019990A1 (en) 2016-07-28 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatement of cancer disease by targetting tumor associated macrophage

Also Published As

Publication number Publication date
CA3147103A1 (en) 2021-01-28
EP4004051A4 (en) 2023-08-23
US11034770B2 (en) 2021-06-15
US11827715B2 (en) 2023-11-28
JP2026026087A (ja) 2026-02-16
US20220289861A1 (en) 2022-09-15
CN114423787B (zh) 2025-01-24
JP2022540806A (ja) 2022-09-20
US20210253733A1 (en) 2021-08-19
MX2022000726A (es) 2022-02-10
TW202116809A (zh) 2021-05-01
US20260103535A1 (en) 2026-04-16
KR20220035452A (ko) 2022-03-22
US20210047424A1 (en) 2021-02-18
PH12022550141A1 (en) 2023-12-04
EP4004051A1 (en) 2022-06-01
IL289829A (en) 2022-03-01
BR112022000876A2 (pt) 2022-04-26
UY38797A (es) 2021-01-29
US11634501B2 (en) 2023-04-25
AU2020315878A1 (en) 2022-03-03
WO2021016128A1 (en) 2021-01-28
US20240101696A1 (en) 2024-03-28
US20240239914A1 (en) 2024-07-18
CN114423787A (zh) 2022-04-29
US12195549B2 (en) 2025-01-14

Similar Documents

Publication Publication Date Title
US12195549B2 (en) Immunomodulatory antibodies and methods of use thereof
JP7767291B2 (ja) 新規のlilrb2抗体およびその使用
IL271696B2 (en) Agonist antibodies that bind human CD137 and their use
JP2022505925A (ja) 抗tim-3抗体
TW202402805A (zh) 抗cd147抗體、醫藥組成物、該等之用途及抗cd147抗體之製造方法
US20240092926A1 (en) Immunomodulatory antibodies and uses thereof
JP2025530159A (ja) Ccr8抗体の医学的使用および投与スケジュール
US20250313631A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
TW202311293A (zh) 免疫療法之組合及其用途
US11896619B2 (en) Compositions and methods for immunotherapy of NPM1c-positive cancer
US20240084029A1 (en) Use of immunomodulatory antibodies to treat fibrotic diseases
CN117062835A (zh) 免疫调节性抗体及其用途
JP2026506893A (ja) Btn3a活性化抗体と免役チェックポイント阻害剤の併用
WO2020171171A1 (ja) 抗hla-dr抗体、およびそのがん治療用途

Legal Events

Date Code Title Description
RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230714

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260409

R150 Certificate of patent or registration of utility model

Ref document number: 7852904

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150